• Topotecan (SKF104864) Cancer Research Workflows

  2026-09-15

  Topotecan (SKF104864) converts a topoisomerase I mechanism into practical assays for viability, DNA damage, apoptosis, and cell-cycle response. This workflow-oriented guide covers glioma, pediatric tumor, combination, and translational experiments while addressing dosing, solubility, controls, and interpretation.

• Cy5 TSA Fluorescence System Kit Workflow

  2026-09-15

  Learn how to apply the Cy5 TSA Fluorescence System Kit to sensitive IHC, ICC, and FISH workflows, with practical conditions for HRP-mediated signal deposition. The guide connects spatial detection of lipid-metabolism markers with the miR-3180 hepatocellular carcinoma study and provides troubleshooting strategies for low signal, background, and imaging artifacts.

• AMG 9810: A Translational TRPV1 Research Framework

  2026-09-14

  AMG 9810 offers a mechanism-first way to interrogate TRPV1 signaling, linking stimulus-specific ion-channel activity with calcium influx, CGRP release, and sensory neuron phenotypes. This perspective outlines how to use the compound rigorously while interpreting emerging metabolic-stress biology without overstating cross-domain evidence.

• Praeruptorin A: Applied Research Workflows

  2026-09-14

  Praeruptorin A supports mechanism-led studies spanning ferroptosis, inflammation, intestinal barrier repair, cardiomyopathy research, and tumor-cell invasion. This workflow shows how to separate pathway modulation from nonspecific cytotoxicity while improving solubility control, orthogonal validation, and assay reproducibility.

• Vancomycin Hydrochloride in Translational Resistance Researc

  2026-09-13

  Vancomycin hydrochloride is more than a routine positive control: its defined D-alanyl-D-alanine binding mechanism can anchor bacterial susceptibility testing, dynamic resistance studies, and Clostridium difficile infection model design. This thought-leadership guide connects glycopeptide biology with semi-mechanistic PKPD principles from contemporary resistance research while clarifying where the evidence is established and where translational validation is still needed.

• Triiodothyronine T3 in Adipose Thermogenesis

  2026-09-12

  Triiodothyronine (T3) provides a reversible, receptor-proximal probe for separating thyroid hormone signaling from SETD7-dependent control of white adipose browning. This workflow combines T3 dose–time testing with thermogenic gene expression, mitochondrial phenotyping, and epistasis experiments to strengthen metabolic disorder research.

• DATCPT Nanocarriers for Orthotopic Pancreatic Cancer

  2026-09-12

  The ACS Nano study introduces DATCPT, a pH/reactive oxygen species-responsive nanocarrier that sequentially adapts its surface charge, remodels tumor stroma, and releases camptothecin in orthotopic pancreatic cancer. Its main contribution is a coordinated strategy for addressing circulation, extracellular matrix, tumor penetration, and metastatic barriers rather than treating each obstacle independently.

• Vancomycin Hydrochloride in Translational Assays

  2026-09-11

  Vancomycin hydrochloride is a mechanistically defined glycopeptide antibacterial agent for Gram-positive susceptibility and resistance studies. This guide extends conventional assay advice by showing how antimicrobial controls can be interpreted alongside tissue-engineering endpoints and infection-model design.

• Dexamethasone (DHAP): From Mechanism to Translation

  2026-09-11

  A translational framework for using Dexamethasone (DHAP) to connect glucocorticoid signaling, immune-cell state, neuroinflammation, stem cell biology, and genetically informed model selection.

• Astrocyte Heterogeneity Across Space and Time

  2026-09-10

  Schroeder et al. developed a cross-species, cross-regional transcriptomic atlas showing that astrocyte identity is strongly patterned by brain location and continues to change after birth. The study combines single-nucleus RNA sequencing with expansion microscopy to connect molecular programs with regional morphology, providing a framework for interpreting astrocyte specialization in mouse and marmoset.

• ASB3-MAVS Control of Antiviral Immunity

  2026-09-10

  The 2024 Cell Death & Differentiation study identifies ASB3 as an inducible E3 ligase that suppresses antiviral innate immunity by promoting K48-linked ubiquitination and proteasomal degradation of MAVS. Its cell and animal experiments connect ASB3 activity with reduced type I interferon signaling and greater susceptibility to influenza A virus, establishing ASB3 as a mechanistic regulator of the RIG-I-like receptor pathway.

• MiR-3180, Lipid Metabolism, and HCC Progression

  2026-09-09

  Hong et al. identify miR-3180 as a regulator that restrains hepatocellular carcinoma by simultaneously limiting SCD1-associated fatty acid synthesis and CD36-mediated lipid uptake. The study combines patient-tissue analysis, molecular validation, cell-function assays, lipid measurements, and xenograft experiments to connect this regulatory axis with tumor growth, invasion, metastasis, and prognosis.

• Pregnenolone Carbonitrile: Assay Design Guide

  2026-09-09

  Pregnenolone Carbonitrile is more than a rodent PXR agonist: it can serve as a calibration probe for disease-state pharmacokinetics, CYP3A regulation, and liver fibrosis assays. This guide connects PCN mechanism with practical experimental decisions informed by a recent MASH pharmacokinetic study.

• SCH772984: An ERK1/2 Lens on Tumor Resistance

  2026-09-08

  SCH772984 is a selective ERK1/2 inhibitor that enables precise interrogation of MAPK signaling, tumor-cell fitness, and treatment resistance. This article connects its assay utility with the Ang II–HIF-1α–HILPDA findings in nasopharyngeal carcinoma while separating established evidence from testable hypotheses.

• TDRD9 siRNA Nanoparticles in P. aeruginosa Lung Injury

  2026-09-07

  The reference study identifies TDRD9 as a suppressor of neutrophil cuproptosis and develops hyaluronic acid-coated peptide nanoparticles to deliver TDRD9 siRNA during Pseudomonas aeruginosa lung infection. Evidence from patient-derived neutrophils, mouse models, and human lung organoids links TDRD9 silencing to reduced neutrophil accumulation, bacterial burden, inflammation, and tissue injury through the PD-L1/CD80/p38 MAPK axis.

8500 records 1/567 page Next 12345 下5页 Last page